Not Signed In - Archemix Announces Initiation Of Phase I Clinical Trial For Novel, Selective Anti-Platelet Aptamer (ARC1779)
Thu, 04 Jan 2007 08:00 AM EST
... Archemix Corp. announced the successful initial dosing with ARC1779 in its first-in-human Phase I study.ARC1779 represents a novel therapeutic principle the reduction of platelet aggregation and thrombosis by inhibition of von Willebrand Factor (vWF). [click link for full article] ...
Related Topics
- Clinical Trials
- Platelet Count
- Platelet Function
- Wrinkles
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Virus
- Tarceva
- Aging Skin
- Aging
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Selective Dorsal Rhizotomy
- Estrogen Receptor Modulators, Selective
- Bevacizumab Injection
- Clinical Growth Charts
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Crohn's Disease
- Pancreatic Cancer
email this page
print this page
bookmark this page
feedback on this page
